News

Task Force Finds Little Guidance For Charcot Foot Tx


 

FROM THE DIABETIC FOOT GLOBAL CONFERENCE

After taking the load off a Charcot foot, practitioners can try bisphosphonates to treat the condition, Dr. Rogers said.

The two agents that have been studied for Charcot foot are pamidronate (Aredia) and alendronate (Fosamax). Pamidromate can be given in a single 90-mg intravenous dose. (You may have to answer questions from the pharmacy because of dosing requirements for patients with renal insufficiency, but there are no dosing requirements if you are giving the dose only once, because the half-life doesn’t really matter in that case, Dr. Rogers said.) Alendronate was given in oral doses of 70 mg weekly in one study in which it was compared with pamidronate for Charcot foot, and it took longer to achieve normal foot temperature.

Another drug studied for Charcot foot is intranasal calcitonin (Miacalcin), which "might make more pathological sense," said Dr. Rogers. It is sprayed once per day in alternating nostrils. It should be given in combination with vitamin D and calcium.

How do you determine whether any of these therapies is working? By using a contact thermometer, you can compare the Charcot foot to the non-Charcot foot. A difference between the two that is greater than 4° F (2° C) is considered significant for inflammation. "Make sure this gets back to [within a] 4° difference before you put them back in their normal footwear," said Dr. Rogers.

Thermal imaging is helpful with patient compliance because it helps the patient see the difference, he said.

After getting the patient into an inactive state, make sure the foot stays protected so it doesn’t develop an ulcer, Dr. Rogers said in conclusion.

Dr. Rogers said he had no conflicts of interest to disclose.

Pages

Recommended Reading

Clinical Presentation May Determine Costs in Critical Limb Ischemia
MDedge Internal Medicine
Liraglutide Beats Other Therapies for Lowering HbA1c Levels
MDedge Internal Medicine
Acromegaly: The New Jan Brady?
MDedge Internal Medicine
Age, Diabetes Affect Arthrodesis Outcomes in Charcot Patients
MDedge Internal Medicine
Endocrine Society Releases Guidelines on Pituitary Incidentalomas
MDedge Internal Medicine
Ultrasound Shows Promise in Wound Healing
MDedge Internal Medicine
Antral Follicle Counts Feasible in Very Young
MDedge Internal Medicine
Denosumab Bone Health Benefits Persist After 5 Years
MDedge Internal Medicine
Study: Diabetes Linked With Cancer and Cancer Mortality Risk
MDedge Internal Medicine
Disproportionate Number of U.S. Adults with Arthritis Obese
MDedge Internal Medicine